Thursday, June 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Emergent Biosolutions, Novartis, Texas A&M to Lead New Biodefense Centers

by Global Biodefense Staff
June 19, 2012

The Department of Health and Human Services (HHS) this week awarded major contracts to establish three new “Centers for Innovation in Advanced Development and Manufacturing.”  The centers will facilitate advanced development of medical countermeasures, and ensure vaccine manufacturing surge capacity for public health emergencies such as pandemic influenza outbreaks.

The awards are being executed under a unique private-public partnership model in which each center will be run by a consortium led by an organization experienced in developing or manufacturing medical countermeasures. Each consortium will retrofit existing facilities or build new ones to incorporate flexible, innovative manufacturing platforms that can be used to manufacture more than one product.

Emergent BioSolutions, with manufacturing facilities in Baltimore and Gaithersburg, Md., will lead one center, working with a network of partners including the University of Maryland, Michigan State University, and Kettering University. This contract is for approximately $163M over the first eight years.

Texas A&M will lead a second center in collaboration with GlaxoSmithKline Vaccines, Lonza, and Kalon Biotherapeutics. This contract is valued at $176M over the first five years.

A third center will be led by Novartis, leveraging existing public-private investments by HHS in their state-of-the-art vaccine facilities in Holly Springs, N.C. Novartis will partner with  North Carolina State University and Duke University for the contract, valued at approximately $60 million over the first four years.

The centers are expected to become fully operational within 2-3 years. The private partners will provide approximately 35 percent of the total cost of the initial building phase. HHS will support the cost of operation and maintenance of the centers in subsequent years.

“Establishing these centers represents a dramatic step forward in ensuring that the United States can produce life-saving countermeasures quickly and nimbly,” said HHS Secretary Kathleen Sebelius. “They will improve our ability to protect Americans’ health in an emergency and help fill gaps in preparedness so that our nation can respond to known or unknown threats.”

The awards are overseen by the Biomedical Advanced Research and Development Authority (BARDA), and each contract can be renewed for up to 25 years. The contracts were executed under Solicitation Number: 11-100-SOL-00011.

Tags: ASPRAwardsBARDAHHSInfluenzaPandemicVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC